ABT-888 - CAS 912445-05-7
Catalog number:
912445-05-7
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
COA:
Inquire
Targets:
PARP
Publictions citing BOC Sciences Products
  • >> More
MSDS:
Inquire
1.Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.
Rodler ET1, Kurland BF2, Griffin M3, Gralow JR3, Porter P3, Yeh RF3, Gadi VK3, Guenthoer J3, Beumer JH2, Korde L3, Strychor S2, Kiesel BF2, Linden HM3, Thompson JA3, Swisher E3, Chai X3, Shepherd S4, Giranda V4, Specht JM3. Clin Cancer Res. 2016 Jan 22. [Epub ahead of print]
PURPOSE: Cisplatin is synergistic with vinorelbine and the PARP inhibitor veliparib, and has antineoplastic activity in triple-negative breast cancer (TNBC) andBRCAmutation-associated breast cancer. This phase I study assessed veliparib with cisplatin and vinorelbine.
2.Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer.
Kummar S1, Wade JL2, Oza AM3, Sullivan D4, Chen AP1, Gandara DR5, Ji J6, Kinders RJ6, Wang L6, Allen D1, Coyne GO1, Steinberg SM1, Doroshow JH7. Invest New Drugs. 2016 Mar 21. [Epub ahead of print]
Background In tumors carrying BRCA mutations, DNA damage caused by standard cytotoxic chemotherapy can be potentiated by poly [ADP-ribose] polymerase (PARP) inhibitors, leading to increased cell death through synthetic lethality. Individuals carrying mutations in BRCA have an increased incidence of triple negative breast cancer (TNBC). In order to assess the role of PARP inhibition in the treatment of TNBC, we conducted a randomized phase II trial of the combination of veliparib, a small molecule PARP inhibitor, with the cytotoxic agent cyclophosphamide versus cyclophosphamide alone in patients with refractory TNBC. Methods Adult patients with TNBC were randomized to receive oral cyclophosphamide 50 mg once daily with or without oral veliparib at 60 mg daily in 21-day cycles. Patients on the cyclophosphamide arm could crossover to the combination arm at disease progression. Results Forty-five patients were enrolled; 18 received cyclophosphamide alone and 21 received the combination as their initial treatment regimen.
3.Veliparib for the treatment of ovarian cancer.
Bogliolo S1, Cassani C1, Dominoni M1, Musacchi V1, Venturini PL2, Spinillo A1, Ferrero S2, Gardella B1. Expert Opin Investig Drugs. 2016 Mar;25(3):367-74. doi: 10.1517/13543784.2016.1146677. Epub 2016 Feb 16.
INTRODUCTION: Ovarian cancer represents the sixth most commonly diagnosed cancer among women, with an incidence of 6.1 cases per 100.000 women and a cumulative lifetime risk of 0.5%. Treatment is based on debulking surgery and platinum-based chemotherapy, with the potential combination with taxane. However, the recently available data on the genetic basis and aetiology of ovarian cancer has led to the development of new anticancer drugs. Poly(ADP-ribose) polymerase (PARP) inhibitors are one of the most promising new classes of targeted agents currently under investigation for the treatment of ovarian cancer. Veliparib is a small molecule that inhibits both PARP-1 and PARP-2 and was originally shown to be efficacious in BRCA-associated tumors.
4.Phase I safety, pharmacokinetic and pharmacodynamic study of the poly (ADP-ribose) polymerase inhibitor veliparib with irinotecan in patients with advanced solid tumors.
LoRusso PM1, Li J2, Burger A3, Heilbrun LK4, Sausville E5, Boerner S6, Smith D7, Pilat MJ8, Zhang J9, Tolaney S10, Cleary JM11, Chen A12, Rubinstein L13, Boerner JL14, Bowditch A9, Cai D15, Bell T15, Wolanski A15, Marrero A16, Zhang Y17, Ji JJ18, Ferry-Ga Clin Cancer Res. 2016 Feb 3. pii: clincanres.0652.2015. [Epub ahead of print]
BACKGROUND: Poly (ADP-ribose) polymerase (PARP) is essential for recognition and repair of DNA damage. In preclinical models, PARP inhibitors modulate topoisomerase I inhibitormediated DNA damage. This Phase I study determined the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), pharmacokinetics (PK) and pharmacodynamics (PD) of veliparib, an orally-bioavailable PARP 1/2 inhibitor, in combination with irinotecan.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PARP Products


CAS 197794-83-5 TFLLR-NH2

TFLLR-NH2
(CAS: 197794-83-5)

TFLLR-NH2, derived from the protease-activated receptor-1 (PAR1), is a selective PAR1 agonist with an EC50 of 1.9 μM.

CAS 344458-15-7 PJ34

PJ34
(CAS: 344458-15-7)

PJ34 is a novel and potential PARP inhibitor with potential anticancer activity. PJ34 has a high affinity for PARP-1 (IC(50) = 20 nM) .

CAS 763113-22-0 Olaparib

Olaparib
(CAS: 763113-22-0)

Olaparib, also known as AZD-2281 or KU-59436, is a small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensiti...

CAS 160003-66-7 Iniparib

Iniparib
(CAS: 160003-66-7)

BSI-201 is a small-molecule prodrug inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP-1) with potential chemosensitizing, radiosensitizing and...

CAS 459868-92-9 Rucaparib Phosphate

Rucaparib Phosphate
(CAS: 459868-92-9)

Rucaparib Phosphate is a selective PARP inhibitor that suppresses the PARP1-mediated DNA repair via binding to PARP1 (Ki = <5 nM). It can be used to sensitize c...

CAS 1345098-78-3 XMD16-5

XMD16-5
(CAS: 1345098-78-3)

XMD16-5is a novel non-receptor tyrosine kinase TNK2 inhibitor (IC50= 16 nM and 77 nM for D163E and R806Q mutant TNK2, respectively)

CAS 344458-19-1 PJ-34 HCL

PJ-34 HCL
(CAS: 344458-19-1)

CAS 934162-61-5 A-966492

A-966492
(CAS: 934162-61-5)

A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with Ki of 1 nM and 1.5 nM, respectively

CAS 1207456-00-5 BMN-673 8R,9S

BMN-673 8R,9S
(CAS: 1207456-00-5)

BMN-673 is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. PARP inhibitor BMN-...

CAS 1038915-73-9 MK-4827 tosylate

MK-4827 tosylate
(CAS: 1038915-73-9)

MK-4827 tosylate is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM. It has a great activity in cancer cells with mutant BRCA-1 and BRCA-2, >330...

CAS 912445-05-7 ABT-888

ABT-888
(CAS: 912445-05-7)

CAS 1419949-20-4 TNKS656

TNKS656
(CAS: 1419949-20-4)

NVP-TNKS656, also known as TNKS656, is a potent and orally active Tankyrase Inhibitor. With an enthalpy-driven thermodynamic signature of binding, highly favor...

CAS 1038915-60-4 niraparib

niraparib
(CAS: 1038915-60-4)

Niraparib is an inhibitor of PARP, which was approved by FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube o...

CAS 1048371-03-4 UPF 1069

UPF 1069
(CAS: 1048371-03-4)

UPF 1069 is a selective PARP2 inhibitor with IC50 of 0.3 μM. It is ~27-fold selective against PARP1.PARP activity is evaluated by utilizing commercially availab...

CAS 1174043-16-3 AZD-2461

AZD-2461
(CAS: 1174043-16-3)

AZD2461 is a novel and potent PARP inhibitor with lower affinity to P-glycoprotein. AZD2641 is currently in Phase I clinical study. The study is being conducted...

CAS 1622262-74-1 BRCA1-IN-1

BRCA1-IN-1
(CAS: 1622262-74-1)

A novel small-molecule-like BRCA1 inhibitor (IC50= 0.53 μM) (Ki= 0.71 μM)

CAS 1380672-07-0 G007-LK

G007-LK
(CAS: 1380672-07-0)

G007-LK is a potent, "rule of 5" compliant and a metabolically stable TNKS1/2 inhibitor. G007-LK displayed high selectivity toward tankyrases 1 and 2 with bioch...

CAS 328543-09-5 AG-14361

AG-14361
(CAS: 328543-09-5)

AG14361 is a PARP-1 inhibitor with Ki < 5 nmol/L. AG14361 is at least 1000-fold more potent than the benzamides. The IC50 for AG14361 is 29 nM in permeabilized ...

AZ0108
(CAS: 1825345-52-5)

AZ0108 is an orally bioavailable, PARP1,2,6 inhibitor that causes a multi-polar spindle phenotype at double digit nM concentrations. AZ0108 has been utilized as...

CAS 912444-00-9 Veliparib

Veliparib
(CAS: 912444-00-9)

Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM, respectively. In HCT-116 and HT-29 cell lines, the ability of ABT-888...

Chemical Structure

CAS 912445-05-7 ABT-888

Quick Inquiry

Verification code

Featured Items